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Abstract
Objectives
The EZSCAN is a non-invasive device that, by evaluating sweat gland function, may detect
subjects with type 2 diabetes mellitus (T2DM). The aim of the study was to conduct a sys-
tematic review and meta-analysis including studies assessing the performance of the EZS-
CAN for detecting cases of undiagnosed T2DM.
Methodology/Principal findings
We searched for observational studies including diagnostic accuracy and performance
results assessing EZSCAN for detecting cases of undiagnosed T2DM. OVID (Medline,
Embase, Global Health), CINAHL and SCOPUS databases, plus secondary resources,
were searched until March 29, 2017. The following keywords were utilized for the systematic
searching: type 2 diabetes mellitus, hyperglycemia, EZSCAN, SUDOSCAN, and sudomotor
function. Two investigators extracted the information for meta-analysis and assessed the
quality of the data using the Revised Version of the Quality Assessment of Diagnostic
Accuracy Studies (QUADAS-2) checklist. Pooled estimates were obtained by fitting the
logistic-normal random-effects model without covariates but random intercepts and using
the Freeman-Tukey Arcsine Transformation to stabilize variances. Heterogeneity was also
assessed using the I2 measure. Four studies (n = 7,720) were included, three of them used
oral glucose tolerance test as the gold standard. Using Hierarchical Summary Receiver
Operating Characteristic model, summary sensitivity was 72.0% (95%CI: 60.0%– 83.0%),
whereas specificity was 56.0% (95%CI: 38.0%– 74.0%). Studies were very heterogeneous
(I2 for sensitivity: 79.2% and for specificity: 99.1%) regarding the inclusion criteria and bias
was present mainly due to participants selection.
Conclusions
The sensitivity of EZSCAN for detecting cases of undiagnosed T2DM seems to be accept-
able, but evidence of high heterogeneity and participant selection bias was detected in most
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Introduction
Worldwide, the burden of type 2 diabetes mellitus (T2DM) is rising rapidly. Currently,
approximately 9% of adults in the world are living with T2DM [1, 2]. Many of the conse-
quences of T2DM affect mainly low- and middle-income countries (LMIC): 1.5 million deaths
worldwide were directly attributable to T2DM in 2012, and more than 80% of these deaths
occurred in LMIC [3, 4]. In addition, about USD$ 548 billion in healthcare expenditures were
due to T2DM in 2013 [5], imposing a large economic burden on individuals and families as
well as health systems, particularly in resource-constrained settings.
Oral glucose tolerance test (OGTT) is considered the gold standard for T2DM diagnosis
according to guidelines [6]. However, conventionally, fasting glucose (FG) is used in most of
healthcare facilities. OGTT and FG require 8 hours of fasting and, in addition, OGTT also
needs the participant to drink a 75-gram glucose solution and wait two hours before a second
blood sample is obtained. In 2009, the American Diabetes Association suggested that glycated
hemoglobin (HbA1c) could be used as a diagnostic tool for T2DM [7]. HbA1c does not require
fasting, but can be expensive and requires a certified laboratory process [8]. Despite the recom-
mended cutoff of 6.5% (48 mmol/mol) for T2DM diagnosis [9], discrepancies between HbA1c
and glycemia in different racial and ethnic groups have been described [10–13].
An important approach to prevent or delay diabetes complications is to identify those indi-
viduals with undiagnosed T2DM [14]. Although universal T2DM screening at the population
level is not practical; there are alternative methods reported in the literature. As early damage
of small nerves can be found since the onset of T2DM [15], some devices have emerged to
assess small-fiber autonomic dysfunction [16]. Among these devices, the EZSCAN (Impeto
Medical, Paris, France), a non-invasive device that performs electrochemical reactions of
eccrine sweat glands, may help to detect participants with diabetes mellitus [17, 18]. The
advantage of the EZSCAN is that its use does not require trained personnel, delivers result
quickly, and does not require active participation of the participants (i.e. fasting). Some studies
have evaluated the potential impact of this device in pre-diabetes, dysglycemia and T2DM
screening [17, 19, 20], but there is limited information regarding its potential for detecting
cases of undiagnosed T2DM. Consequently, we conducted a systematic review and meta-anal-
ysis of observational studies to assess the performance of the EZSCAN for undiagnosed
T2DM. Our hypothesis was focused on sensitivity, expecting at least a performance of 75%.
Materials and methods
Study selection
We searched for observational studies including diagnostic accuracy results assessing EZSCAN
for undiagnosed T2DM, conducted in different parts of the world, but reported in English.
Studies were excluded if they were only abstracts or review articles, enrolled individuals aged
<18 years or cases with type 1 diabetes mellitus, and defined type 2 diabetes mellitus (T2DM)
by using blood markers other than OGTT or FG (i.e. HbA1c). The rationale for this decision
was based on discrepancies between HbA1c and glycemia in different racial and ethnic groups
and that HbA1c is not commonly used for undiagnosed T2DM.
EZSCAN and undiagnosed diabetes
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Data sources and searches
A comprehensive literature search using the Ovid database (PubMed-Medline, Embase, Global
Health, and Health Management Information Consortium) as well as CINAHL, and SCOPUS,
until March 29, 2017, was conducted. The following keywords were utilized for the systematic
searching: type 2 diabetes mellitus, hyperglycemia, EZSCAN, SUDOSCAN, and sudomotor
function [16]. The term SUDOSCAN was also included in the search strategy as it uses the
same principle (i.e. sudomotor function assessment) for detecting diabetic neuropathy [21,
22]. The search strategy of Ovid is available in S1 Table. The Impeto Medical website was also
searched to find other published manuscripts [19].
Data extraction and quality assessment
Titles and abstracts of retrieved articles were reviewed independently by two investigators to
select potentially relevant articles, and disagreements were discussed and solved by consensus.
Using a standardized data extraction form, we collected information on lead author, publica-
tion year, country, study design, inclusion criteria, used gold standard, sample size, mean age,
percentage of male participants, and different indicators of the performance of the EZSCAN to
detect undiagnosed T2DM (outcome, area under the curve, cut-off, sensitivity, specificity,
among others).
Quality assessment of individual studies was performed to identify potential sources of bias
and to limit, if possible, the effect of these biases on the conclusions of the review. For this, the
Revised Version of the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2)
checklist was used [23]. This tool included risk of bias assessment (i.e. participant selection,
index test, reference standard, and flow and timing) as well as applicability.
Data synthesis and analysis
The primary outcome of interest was undiagnosed T2DM (i.e. newly-diagnosed T2DM) iden-
tified by OGTT or FG. Secondary outcomes included other glucose metabolism disorders such
as impaired glucose tolerance, impaired fasting glucose and, dysglycemia.
Statistical analyses were performed using Stata version 13 for Windows (StataCorp, College
Station, TX, US). Our systematic review followed the Preferred Reporting Items for Systematic
Review and Meta-Analysis (PRISMA, See S1 Checklist), the Guidelines for Meta-Analyses and
Systematic Reviews of Observational Studies (MOOSE) [24] as well as the Cochrane Hand-
book for Diagnostic Test Accuracy Reviews [25]. Initially, the studies included in the system-
atic review were described, including: publication year, country, study design, inclusion
criteria, gold standard, sample size, mean age, and proportion of males. In addition, the perfor-
mance of the EZSCAN in each study was tabulated, and the area under the receiver operating
characteristic (ROC) curve (AUC), best cut-off, sensitivity, and specificity, and their respective
95% confidence intervals (95%CI) were reported, if available.
A meta-analysis of the performance of the EZSCAN was conducted using data from studies
with undiagnosed T2DM as outcome. Information used in meta-analysis was taken as pro-
posed by manuscripts according to the best EZSCAN threshold cut-off reported. The “meta-
prop” command in STATA was used to estimate sensitivity, specificity and positive (PPV) and
negative (NPV) predictive values and their respective 95%CI [26]. The “metaprop” command
obtains a pooled estimate as a weighted average, by fitting the logistic-normal random-effects
model without covariates but random intercepts. The pooled estimate was then calculated
using the Freeman-Tukey Arcsine Transformation to stabilize the variances as suggested in lit-
erature [27]. In addition, a graph containing the plot of the Hierarchical Summary Receiver
Operating Characteristic (HS-ROC) model [28], a summary point of sensitivity and specificity
EZSCAN and undiagnosed diabetes
PLOS ONE | https://doi.org/10.1371/journal.pone.0187297 October 30, 2017 3 / 11
and the 95% confidence region for that point was obtained by using the “metandiplot” com-
mand [29]. Heterogeneity of estimates and 95%CI was determined using the I2 measure [30].
Results
Study characteristics
A total of 1,461 citations were identified through our systematic search, with a further 16 cita-
tions identified using the Impeto Medical website. After excluding duplicates (n = 330), a total
of 1,147 citations were independently screened, of which 31 were retrieved for detailed assess-
ment (agreement between reviewers, 97.2%, kappa = 0.61, p<0.001). Of the 31 revised manu-
scripts, 27 did not fit our inclusion criteria (Fig 1); therefore, four studies were included in the
systematic review.
The characteristics of the studies included in the systematic review are shown in Table 1.
All the four studies were cross-sectional in nature. A total of 7,720 individuals were included
Fig 1. Flowchart of database searches and articles included in the systematic review. T2DM: Type 2
diabetes mellitus, HbA1c = glycated hemoglobin, IGM = impaired glucose metabolism.
https://doi.org/10.1371/journal.pone.0187297.g001
Table 1. Characteristics of the studies included in the systematic review.
Study, publication year Country Study
design
Inclusion criteria Gold
standard
Size Mean
age
%
male
Chen X, 2015 [32] China Cross-
sectional
Subjects in routine health check visiting a Community
Hospital, at risk of T2DM (age 45 years).
OGTT 270 58.6 32%
Ramachadran A, 2010
[33]
India Cross-
sectional
Individuals in specific clinics aged between 21–75 years. OGTT 212 43.4 45%
Sanchez-Hernandez O,
2015 [34]
Mexico Cross-
sectional
Individuals recruited in a clinic in Mexico;18 years,
apparently healthy and attending a full check-up.
FG 1,414 44.7 50%
Yang Z, 2013 [31] China Cross-
sectional
Individuals from two communities in Shanghai aged 40
+ years.
OGTT 5,824 58.3 40%
FG = fasting glucose; OGTT = oral glucose tolerance test.
https://doi.org/10.1371/journal.pone.0187297.t001
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from all the studies, but 5,824 subjects came from a single study [31]. This latter study enrolled
individuals from the general population, whereas the remaining three studies recruited partici-
pants at clinics, mainly individuals going for healthy check-ups.
Risk of bias
Overall, participant selection bias was present in 3 out of 4 of the studies included in the meta-
analysis [32–34]: individuals under healthy check-ups were enrolled in the original studies (S2
Table). In addition, flow and timing was unclear in the same three studies, and the gold stan-
dard (i.e. OGTT) was not used in one of the studies [34].
Meta-analysis: EZSCAN performance for undiagnosed T2DM
Undiagnosed T2DM was the outcome of interest in the four studies (Table 2). Other outcomes
evaluated in these papers included impaired glucose tolerance [32, 33], impaired fasting glu-
cose [34] and dysglycemia [31].
When undiagnosed T2DM was the outcome, only two studies reported results of AUC
ranging from 53% to 73% [32, 34]. In addition, 2 studies used 50% as the suggested EZSCAN
cut-off for undiagnosed T2DM screening [32, 33], whereas one used 34% [34], and the last one
utilized 30% [31]. Sensitivity varied from 53% to 81%, whilst specificity ranged from 43% to
70%. Finally, positive predictive values (PPV) varied from 10% to 40%, whereas negative pre-
dictive values (NPV) ranged from 71% to 98%.
When using HS-ROC (Fig 2), summary sensitivity was 72.0% (95%CI: 60.0%– 83.0%), spec-
ificity was 56.0% (95%CI: 38.0%– 74.0%), PPV was 24% (95%CI: 12.0%– 37.0%), and NPV was
89% (95%CI: 82.0%– 97.0%). In addition, positive and negative likelihood ratios were 1.68
(95%CI: 1.35–2.10) and 0.48 (95%CI: 0.36–0.66), respectively, whereas the DOR was 3.49 (95%
CI: 2.18–5.57). Heterogeneity for sensitivity was 79.2% (95%CI: 44.0%– 92.0%), whereas for
specificity was 99.1% (95%CI: 98.5%– 99.6%).
Table 2. Performance of the EZScan in the studies included in the systematic review.
Study, publication year Outcome AUC Cut-off Sensitivity Specificity
Chen X, 2015 [32] IGT 78%
(72%–83%)
37% 82%
(72%–90%)
63%
(55%–71%)
Chen X, 2015 [32] T2DM 53%
(43%–62%)
50% 53% (36%–69%) 59%
(47%–70%)
Ramachadran A, 2010 [33] IGT — 50% 70%
(not reported)
54%
(not reported)
Ramachadran A, 2010 [33] T2DM — 50% 75%
(not reported)
54%
(not reported)
Sanchez-Hernandez O, 2015 [34] IFG 65%
(not reported)
27% 69%
(not reported)
56%
(not reported)
Sanchez-Hernandez O, 2015 [34] T2DM 73%
(not reported)
34% 73%
(not reported)
70%
(not reported)
Yang Z, 2013 [31] IFG, IGT or T2DM — 30% 73%
(71%-75%)
46%
(45%-48%)
Yang Z, 2013 [31] T2DM — 30% 81%
(78%-83%)
43%
(42%-44%)
IFG = Impaired fasting glucose; IGT = Impaired glucose tolerance; T2DM = type 2 diabetes mellitus; AUC = area under the curve.
Values in brackets are 95% confidence intervals (95%CI).
https://doi.org/10.1371/journal.pone.0187297.t002
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Discussion
Summary of evidence
According to the results of this systematic review and meta-analysis, the performance of the
EZSCAN in the detection of cases undiagnosed T2DM can be considered acceptable especially
in the case of sensitivity, and even comparable to different well-known T2DM risk scores [35,
36]. To put in context our findings, the sensitivity of HbA1c, using a cut-off6.5% (48 mmol/
mol), for detecting undiagnosed diabetes was 52.8% using OGTT as the gold standard [37].
Thus, apparently, the EZSCAN might perform better that HbA1c although other studies are
needed to corroborate this.
There are, however, some limitations that need to be highlighted. First, there is a risk of bias
based on participant selection that can complicate extrapolation of results: many of the studies
were performed in clinical context (i.e. clinical check-ups) instead of using population level
assessments. Second, a high level of heterogeneity between studies was found (greater than
75%) in all estimations (i.e. sensitivity, specificity, etc). Since a small number of studies were
included in the meta-analysis; results need to be cautiously interpreted despite of the fact that
random effect models were used in calculations [38]. In addition, heterogeneity in results of the
EZSCAN performance can be secondary to characteristics of the context and individuals: pre-
dictive values as well as likelihood ratios can depend on baseline risk of evaluated subjects. For
example, the association of body mass index–one of the variables used in scoring individuals
Fig 2. Performance of EZScan in the screening of T2DM: Meta-analysis using HSROC. Sensitivity =
72.0% (95%CI: 60.0%–83.0%); specificity = 56.0% (95%CI: 38.0%–74.0%); likelihood ratio positive = 1.68
(95%CI: 1.35–2.10); likelihood ratio negative = 0.48 (95%CI: 0.36–0.66); DOR = 3.49 (95%CI: 2.18–5.57).
HSROC curve is shown only for sensitivities and specificities at least as large as the smallest study-specific
estimates.
https://doi.org/10.1371/journal.pone.0187297.g002
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through EZSCAN–with the risk of diabetes may vary in different populations [39], and explain
variability found in this report. Finally, although there is a suggested EZSCAN cut-off for defin-
ing T2DM in the population (50%), our results showed heterogeneity of this cut-off between
studies and populations assessed: only two studies used the proposed 50% cut-off [32, 33],
whereas the other studies were below that value. Thus, the device needs to be validated in differ-
ent populations.
The principle of the EZSCAN, based on the evaluation of sudomotor function, relies on the
assessment of chloride concentrations using reverse iontophoresis and chronoamperometry to
detect insulin resistance and T2DM [18]. The EZSCAN has showed reproducible results in sev-
eral conditions with low impact of usual physiological variations due to its focus on chloride
concentrations, instead of sweat rates as used by other methods [40]. This device deliver results
rapidly (i.e. in 2 to 3 minutes) and does not require invasive blood testing or fasting. Moreover,
no safety problems have been reported during its use. Of note, although the EZSCAN has been
designed to detect individuals with undiagnosed T2DM [18], some of the studies have focused
on the ability of the device to detect impaired fasting glucose [17, 41, 42], dysglycemia [31, 33],
metabolic syndrome [20], or even, complications related to T2DM [43, 44]. On the other hand,
a relatively recent paper combined the performance of this device with conventional risk scores
and reported limited improvement in the model given by the sum of EZSCAN plus risk score in
Chinese population [31]. However, authors claimed that other studies are needed to determine
the clinical relevance of EZSCAN in detecting cases of diabetes.
Public health relevance
Sensitivity and specificity estimates from this review may be used to better understand EZS-
CAN testing in real practice. For example, in a given setting with a prevalence of undiagnosed
T2DM of 10% and assuming a cut-off value of 50% as suggested by the provider, if 1,000 indi-
viduals were screened using the EZSCAN, based on tool sensitivity, the device would detect 72
undiagnosed T2DM cases and 28 would be missing (false negatives). On the other hand, from
the 900 individuals without the disease, 396 would be false positives and classified as having
T2DM with the subsequent need of a confirmatory test. Thus, we would only need to perform
468 OGTT for those positive for EZSCAN, instead of the total population. If the prevalence
were higher (i.e. 20% instead of 10%), of the 1,000 individuals, the device would detect 144
individuals based on its sensitivity, but 56 cases would be missing (false negatives). Of the 800
subjects without the disease, 352 would be false positives and classified as having T2DM with
the need of a confirmatory test. Therefore, 496 OGTT would be needed but missing 56 cases as
false negatives. On the other hand, summary estimates of the positive and negative likelihood
ratios were very similar to values compatible with minimal change in the likelihood of disease.
Thus, if positive and negative likelihood ratios of>10 and<0.1, respectively, were available,
this would provide strong evidence to confirm and discard undiagnosed T2DM [45].
Using EZSCAN for detecting undiagnosed T2DM cases can have some advantages includ-
ing the short time spent in conducting the test, the fact that fasting is not required, and the
repeated used of the device can compensate its cost. However, some disadvantages also arise.
Although, the EZSCAN can potentially reduce the resources implied in assessing populations
for detecting T2DM cases, the number of false negatives (i.e. individuals with undiagnosed
T2DM that are not detected by the device) increased when the prevalence of diabetes in-
creased. On the other hand, literature suggested that EZSCAN cutoff should be estimated by
each population instead of only using the cut-off given by the provider [31, 34, 46].
To our knowledge there is no information regarding the cost-effectiveness of the EZSCAN
for detecting one undiagnosed case of T2DM in addition to the lack of data related to the
EZSCAN and undiagnosed diabetes
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potential performance for future risk of T2DM. Only one study has assessed the utility of this
device longitudinally (2-year follow-up) but in a small sample [17]. In this study, the authors
found an association between the EZSCAN score and T2DM progression although results
needed further confirmation. Thus, the EZSCAN might have potential implications for T2DM
prevention although population-based validation may be necessary to define appropriate cut-
off for appropriate results interpretation.
Limitations
One of the limitations of this review is the representativeness of the results characterized by
bias in participants’ selection as well as the lack of a true gold standard in some of the studies
(i.e. FG was used in one study instead of OGTT). In addition, characteristics of the study popu-
lation were poorly reported and this is reflected in the quality assessment. As all the studies
assessing EZSCAN were recently published (from 2010 and onwards); authors should have
been utilized the Standards for Reporting Diagnostic Accuracy Studies (STARD) to guide their
manuscripts’ writing [47]. Future studies should follow these guidelines to guarantee an appro-
priate reporting of diagnostic studies.
Given the limited number of studies assessed, EZSCAN threshold was not meta-analyzed as
the performance of the diagnostic test depends on the population in which the test is used.
Thus, for our analyses, pooled sensitivity and specificity were calculated using the best cut-off
reported by studies and not the same in all cases. In addition, there is limited data evaluating
the potential impact of EZSCAN for undiagnosed T2DM at the population level. Future stud-
ies should be focused on population-based samples instead of referral health facilities, but also
in different ethnic groups as only studies from China and India were used in this review. A
study from Mexican population was also included in the meta-analysis, but the sample was
biased and FG was used as gold standard [34]. Moreover, as the number of studies included in
the analysis was small, publication bias was not assessed (usual tests for publication bias are
underpowered when <10 studies are evaluated).
In summary, the sensitivity of the EZSCAN for undiagnosed T2DM screening seems to be
acceptable but the evidence is limited because of the presence of participant selection bias in
most of the included studies in the meta-analysis. The performance of the EZSCAN warrants
confirmation in different populations, using the appropriate gold standard, and population-
based samples. Moreover, adequate report of findings and longitudinal utility of the EZSCAN
is also compulsory.
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